Indication
Chronic hepatitis C - genotype 3
Chronic hepatitis C - genotype 3 is a persistent viral infection of the liver caused by the genotype 3 strain of the hepatitis C virus, defined clinically by detectable viral RNA persisting for six months or longer. Read more about Chronic hepatitis C - genotype 3
30 drugs 14 manufacturers
Drugs that treat it
Common Chronic hepatitis C - genotype 3 therapies.
RIBAVIRIN
RIBAVIRIN
RIBAVIRIN
RIBAVIRIN
RIBAVIRIN
RIBAVIRIN
PEGASYS PROCLICK (peginterferon alfa-2a)
PEGINTRON (peginterferon alfa-2b)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonChronic hepatitis C - genotype 3 is a persistent viral infection of the liver caused by the genotype 3 strain of the hepatitis C virus, defined clinically by detectable viral RNA persisting for six months or longer.
Primarily affecting hepatic tissue in infected pediatric and adult populations, it exhibits distinct pathophysiologic behavior compared to other viral strains.
Genotype 3 is notably characterized by virus-induced hepatic steatosis, accelerated rates of fibrosis progression, and an increased risk of developing cirrhosis and hepatocellular carcinoma.
While frequently asymptomatic in its early stages, progressive infection can lead to end-stage liver disease, portal hypertension, and hepatic decompensation.
- cdc.gov
Chronic hepatitis C - genotype 3 is a persistent viral infection of the liver caused by the genotype 3 strain of the hepatitis C virus, defined clinically by detectable viral RNA persisting for six months or longer Primarily affecting hepatic tissue in infected pediatric and adult populations, it exhibits distinct pathophysiologic behavior compared to other viral strains
- merckmanuals.com
Chronic hepatitis C - genotype 3 is a persistent viral infection of the liver caused by the genotype 3 strain of the hepatitis C virus, defined clinically by detectable viral RNA persisting for six months or longer While frequently asymptomatic in its early stages, progressive infection can lead to end-stage liver disease, portal hypertension, and hepatic decompensation
- aasld.org
Primarily affecting hepatic tissue in infected pediatric and adult populations, it exhibits distinct pathophysiologic behavior compared to other viral strains
- nih.gov
Genotype 3 is notably characterized by virus-induced hepatic steatosis, accelerated rates of fibrosis progression, and an increased risk of developing cirrhosis and hepatocellular carcinoma
- tandfonline.com
Genotype 3 is notably characterized by virus-induced hepatic steatosis, accelerated rates of fibrosis progression, and an increased risk of developing cirrhosis and hepatocellular carcinoma
- natap.org
Genotype 3 is notably characterized by virus-induced hepatic steatosis, accelerated rates of fibrosis progression, and an increased risk of developing cirrhosis and hepatocellular carcinoma
- mayoclinic.org
While frequently asymptomatic in its early stages, progressive infection can lead to end-stage liver disease, portal hypertension, and hepatic decompensation
- aasld.org
While frequently asymptomatic in its early stages, progressive infection can lead to end-stage liver disease, portal hypertension, and hepatic decompensation
Personalize your experience
Follow Chronic hepatitis C - genotype 3 and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.